H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of $103.00. The company’s shares closed yesterday at $27.15.
Burns covers the Healthcare sector, focusing on stocks such as Portage Biotech Inc, BioNTech SE, and Springworks Therapeutics. According to TipRanks, Burns has an average return of -21.0% and a 23.35% success rate on recommended stocks.
Springworks Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $103.00.
SWTX market cap is currently $1.69B and has a P/E ratio of -5.83.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SWTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm’s products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Read More on SWTX:
- SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
- SpringsWorks price target raised to $103 from $94 at H.C. Wainwright
- SpringWorks Therapeutics announces data from Phase 3 DeFi trial
- SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
- SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma